These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 12798323)

  • 21. The development of novel 1,2-dihydro-pyrimido[4,5-c]pyridazine based inhibitors of lymphocyte specific kinase (Lck).
    Sabat M; Vanrens JC; Brugel TA; Maier J; Laufersweiler MJ; Golebiowski A; De B; Easwaran V; Hsieh LC; Rosegen J; Berberich S; Suchanek E; Janusz MJ
    Bioorg Med Chem Lett; 2006 Aug; 16(16):4257-61. PubMed ID: 16757169
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Discovery and SAR of 2-amino-5-[(thiomethyl)aryl]thiazoles as potent and selective Itk inhibitors.
    Das J; Liu C; Moquin RV; Lin J; Furch JA; Spergel SH; Doweyko AM; McIntyre KW; Shuster DJ; O'Day KD; Penhallow B; Hung CY; Kanner SB; Lin TA; Dodd JH; Barrish JC; Wityak J
    Bioorg Med Chem Lett; 2006 May; 16(9):2411-5. PubMed ID: 16481166
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Optimization of 2-phenylaminoimidazo[4,5-h]isoquinolin-9-ones: orally active inhibitors of lck kinase.
    Goldberg DR; Butz T; Cardozo MG; Eckner RJ; Hammach A; Huang J; Jakes S; Kapadia S; Kashem M; Lukas S; Morwick TM; Panzenbeck M; Patel U; Pav S; Peet GW; Peterson JD; Prokopowicz AS; Snow RJ; Sellati R; Takahashi H; Tan J; Tschantz MA; Wang XJ; Wang Y; Wolak J; Xiong P; Moss N
    J Med Chem; 2003 Apr; 46(8):1337-49. PubMed ID: 12672234
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel 2-aminopyrimidine carbamates as potent and orally active inhibitors of Lck: synthesis, SAR, and in vivo antiinflammatory activity.
    Martin MW; Newcomb J; Nunes JJ; McGowan DC; Armistead DM; Boucher C; Buchanan JL; Buckner W; Chai L; Elbaum D; Epstein LF; Faust T; Flynn S; Gallant P; Gore A; Gu Y; Hsieh F; Huang X; Lee JH; Metz D; Middleton S; Mohn D; Morgenstern K; Morrison MJ; Novak PM; Oliveira-dos-Santos A; Powers D; Rose P; Schneider S; Sell S; Tudor Y; Turci SM; Welcher AA; White RD; Zack D; Zhao H; Zhu L; Zhu X; Ghiron C; Amouzegh P; Ermann M; Jenkins J; Johnston D; Napier S; Power E
    J Med Chem; 2006 Aug; 49(16):4981-91. PubMed ID: 16884310
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Validated quantitative structure-activity relationship analysis of a series of 2-aminothiazole based p56(Lck) inhibitors.
    Li J; Du J; Xi L; Liu H; Yao X; Liu M
    Anal Chim Acta; 2009 Jan; 631(1):29-39. PubMed ID: 19046675
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Discovery and SAR of 2-amino-5-(thioaryl)thiazoles as potent and selective Itk inhibitors.
    Das J; Furch JA; Liu C; Moquin RV; Lin J; Spergel SH; McIntyre KW; Shuster DJ; O'Day KD; Penhallow B; Hung CY; Doweyko AM; Kamath A; Zhang H; Marathe P; Kanner SB; Lin TA; Dodd JH; Barrish JC; Wityak J
    Bioorg Med Chem Lett; 2006 Jul; 16(14):3706-12. PubMed ID: 16682193
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis and antitumour activity of new dendritic polyamines-(imide-DNA-intercalator) conjugates: potent Lck inhibitors.
    Braña MF; Domínguez G; Sáez B; Romerdahl C; Robinson S; Barlozzari T
    Eur J Med Chem; 2002 Jul; 37(7):541-51. PubMed ID: 12126773
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pyrrolo[2,3-d]pyrimidines containing an extended 5-substituent as potent and selective inhibitors of lck II.
    Burchat AF; Calderwood DJ; Hirst GC; Holman NJ; Johnston DN; Munschauer R; Rafferty P; Tometzki GB
    Bioorg Med Chem Lett; 2000 Oct; 10(19):2171-4. PubMed ID: 11012022
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity.
    DiMauro EF; Newcomb J; Nunes JJ; Bemis JE; Boucher C; Buchanan JL; Buckner WH; Cee VJ; Chai L; Deak HL; Epstein LF; Faust T; Gallant P; Geuns-Meyer SD; Gore A; Gu Y; Henkle B; Hodous BL; Hsieh F; Huang X; Kim JL; Lee JH; Martin MW; Masse CE; McGowan DC; Metz D; Mohn D; Morgenstern KA; Oliveira-dos-Santos A; Patel VF; Powers D; Rose PE; Schneider S; Tomlinson SA; Tudor YY; Turci SM; Welcher AA; White RD; Zhao H; Zhu L; Zhu X
    J Med Chem; 2006 Sep; 49(19):5671-86. PubMed ID: 16970394
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pyrazolo[3,4-d]pyrimidines containing an extended 3-substituent as potent inhibitors of Lck -- a selectivity insight.
    Burchat AF; Calderwood DJ; Friedman MM; Hirst GC; Li B; Rafferty P; Ritter K; Skinner BS
    Bioorg Med Chem Lett; 2002 Jun; 12(12):1687-90. PubMed ID: 12039591
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Discovery of pyrimidine benzimidazoles as Src-family selective Lck inhibitors. Part II.
    Zhang G; Ren P; Gray NS; Sim T; Wang X; Liu Y; Che J; Dong W; Tian SS; Sandberg ML; Spalding TA; Romeo R; Iskandar M; Wang Z; Seidel HM; Karanewsky DS; He Y
    Bioorg Med Chem Lett; 2009 Dec; 19(23):6691-5. PubMed ID: 19854052
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Small molecule inhibitors of Lck: the search for specificity within a kinase family.
    Meyn MA; Smithgall TE
    Mini Rev Med Chem; 2008 Jun; 8(6):628-37. PubMed ID: 18537718
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis of antitumor dendritic imides.
    Braña MF; Domínguez G; Sáez B; Romerdahl C; Robinson S; Barlozzari T
    Bioorg Med Chem Lett; 2001 Dec; 11(23):3027-9. PubMed ID: 11714603
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A new strategy for the construction of the imidazo[1,5-a]quinoxalin-4-one ring system and its application to the efficient synthesis of BMS-238497, a novel and potent Lck inhibitor.
    Chen BC; Zhao R; Bednarz MS; Wang B; Sundeen JE; Barrish JC
    J Org Chem; 2004 Feb; 69(3):977-9. PubMed ID: 14750833
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Discovery of thienopyridines as Src-family selective Lck inhibitors.
    Abbott L; Betschmann P; Burchat A; Calderwood DJ; Davis H; Hrnciar P; Hirst GC; Li B; Morytko M; Mullen K; Yang B
    Bioorg Med Chem Lett; 2007 Mar; 17(5):1167-71. PubMed ID: 17234410
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The protein tyrosine kinase p56(lck) regulates the serine-base exchange activity in Jurkat T cells.
    Marhaba R; Dumaurier MJ; Pelassy C; Batoz M; Peyron JF; Breittmayer JP; Aussel C
    FEBS Lett; 1997 Mar; 405(2):163-6. PubMed ID: 9089283
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The development of novel and selective p56lck tyrosine kinase inhibitors.
    Bullington JL; Cameron JC; Davis JE; Dodd JH; Harris CA; Henry JR; Pellegrino-Gensey JL; Rupert KC; Siekierka JJ
    Bioorg Med Chem Lett; 1998 Sep; 8(18):2489-94. PubMed ID: 9873567
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Discovery of pyrimidine benzimidazoles as Lck inhibitors: part I.
    Zhang G; Ren P; Gray NS; Sim T; Liu Y; Wang X; Che J; Tian SS; Sandberg ML; Spalding TA; Romeo R; Iskandar M; Chow D; Martin Seidel H; Karanewsky DS; He Y
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5618-21. PubMed ID: 18793846
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ezrin is a substrate for Lck in T cells.
    Autero M; Heiska L; Rönnstrand L; Vaheri A; Gahmberg CG; Carpén O
    FEBS Lett; 2003 Jan; 535(1-3):82-6. PubMed ID: 12560083
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lck is involved in interleukin-2 induced proliferation but not cell survival in human T cells through a MAP kinase-independent pathway.
    Brockdorff J; Nielsen M; Kaltoft K; Mustelin T; Röpke C; Svejaard A; Geisler C; Odum N
    Eur Cytokine Netw; 2000 Jun; 11(2):225-31. PubMed ID: 10903801
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.